GO
Loading...

Biotechnology

More

  • Here's what's pushing biotech lower: Expert     Friday, 11 Apr 2014 | 8:42 AM ET

    I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.

  • Studies: Lab-grown nostrils, vaginas working well Friday, 11 Apr 2014 | 4:25 AM ET

    LONDON— Two new studies describe the latest achievements in growing body parts in a lab and transplanting them into people, this time with nostrils and vaginas. Martin Birchall, of The Ear Institute at University College London, who co-authored an accompanying commentary.

  • *Biotech indexes have worst day since August 2011. *Bed, Bath& Beyond slumps after earnings. NEW YORK, April 10- U.S. stocks sank on Thursday, with the S&P 500 turning negative for the year and the Nasdaq falling its most in a day since June 2012 as investors again sold high-flying names in the technology and biotech sectors and sought shelter in defensive names.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

  • The biotech parade     Wednesday, 9 Apr 2014 | 12:27 PM ET

    CNBC's Meg Tirrell provides insight on the increase in biotech IPOs, and what to expect from both Cerulean Pharma & Adamas Pharmaceuticals ahead of their IPO pricing Wednesday night.

  • There’s still value in biotech stocks: Citi pro Monday, 7 Apr 2014 | 6:23 PM ET

    Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.

  • Diversifying your pharma portfolio     Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.

  • Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.

  • Why investors should be exposed to biotech     Monday, 31 Mar 2014 | 5:30 AM ET

    Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.

  • Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.

  • Why drug treatment prices vary     Wednesday, 26 Mar 2014 | 1:08 PM ET

    The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 3:37 PM ET

    CNBC's Sheila Dharmarajan discusses the beat down biotech stocks have recently taken and gives 3 reasons why investors should stick with the sector.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 1:07 PM ET

    CNBC's Sheila Dharmarajan reports why analysts think investors should stick with the biotech sector.

  • Gilead's next move     Tuesday, 25 Mar 2014 | 12:13 PM ET

    Gilead received a letter from U.S. lawmakers questioning the pricing of its hepatitis c drug Solvadi. Mark Schoenebaum, ISI Health Care Research Group senior managing director, provides perspective.

  • Cramer: Need to see IPO competition cease     Tuesday, 25 Mar 2014 | 9:01 AM ET

    CNBC's Jim Cramer shares his thoughts on yesterday's Nasdaq selloff and the slumping biotech sector.

  • Biotech could see more weakness: Pro     Monday, 24 Mar 2014 | 2:03 PM ET

    Barbara Ryan, FTI Consulting, and Matt Maley, MillerTabek and Company, discuss what has propelled the massive sell-off in the biotech sector.

  • Biotech's big drop     Monday, 24 Mar 2014 | 1:01 PM ET

    CNBC's Dominic Chu digs into the battered biotech sector and reveals which stocks are still sliding.

Most Popular Video

Tuesday, 15 Apr 2014 | 7:31 PM ET

Hiroshi Miyoshi, Mitsubishi CEO for Turkey and Central Asia, describes Turkey's appeal to Japanese firms, who invested $500 million in the emerging market last year.

Tuesday, 15 Apr 2014 | 4:07 PM ET

"Yahoo's core business is still limping along," says Colin Gillis, BGC Financial, while providing instant reaction to Yahoo's quarterly numbers. "Shark Tank" investor Kevin O'Leary and "The Profit's" Marcus Lemonis weigh in.

Tuesday, 15 Apr 2014 | 11:31 PM ET

John Sculley, former Apple CEO and Managing Partner at Inflexionpoint, discusses his company's acquisitions in Singapore and India.